oral glp 1 inhibitor First Time: Orally Available GLP-1 Agonist More Effective than DPP-IV | DZD Head-to-head trial shows Eli Lilly's

Batisti and Kudla 2012

86 ColletT-HDubernBMokrosinskiJConnorsHKeoghJMde OliveiraEMet al

As clinicians increasingly encounter patients with IBD as well as obesity, diabetes, or metabolic liver disease, there is a clear need to synthesize what is known about safety, metabolic effects, and IBD-specific outcomes to support evidence-informed clinical decision-making, explains senior investigator and study author Jolle St-Pierre, MD, PhD, FRCPC, a clinical assistant professor in the Division of Gastroenterology and Hepatology at the University of Calgary, Canada, in an email to Gastro Today

Expression of BCL2 associated athanogene-1 is up-regulated in canine Malignant mammary tumors

Storage requirements differ between single-use and multi-dose pens, and some products permit limited room temperature storage

DeLong L, Burkhart NW